More specifically, it seems that urinary CCL7 may present a useful biomarker for AKI, while the specific blockade of the CCL7 chemokine in the blood could prove to be a useful strategy to reduce the inflammatory kidney infiltration, thereby ameliorating AKI without affecting the rest of the inflammatory cells that fight infections [41,42]. This evidence concerns the gene CCL7 and infection.